Spyre Therapeutics (SYRE) TD Cowen 46th Annual Health Care Conference summary

Strategic vision and pipeline overview

• Focused on developing indication-leading therapies for autoimmune diseases, initially targeting inflammatory bowel disease (IBD) and expanding into rheumatic diseases.

• Pipeline includes optimized monotherapies against alpha-4 beta-7, TL1A, and IL-23, engineered for improved potency, longer half-life, and greater patient convenience.

• Emphasis on combination therapies to address the heterogeneity and therapeutic ceiling in IBD, aiming for additive efficacy by blocking multiple pathways.

• TL1A viewed as a pipeline-in-a-product with potential efficacy across a range of autoimmune diseases.

• Rapid progress with potential to be first and best in class in rheumatic diseases, including RA, psoriatic arthritis, and axial spondyloarthritis.

Clinical development and trial design

• Six phase II proof-of-concept readouts expected in 2024, with IBD monotherapy data starting next quarter and rheumatic disease data by year-end.

• Phase I studies show molecules have improved potency and over three times the half-life of first-generation agents, enabling dosing as infrequently as two to four times per year.

• Platform study design allows simultaneous testing of monotherapies and combinations, optimizing trial efficiency and resource use.

• Enrollment for key cohorts is ahead of schedule, with initial readouts to focus on objective measures and clinical remission.

• Maintenance data from these studies expected in 2027, nine to twelve months after induction data.

Market landscape and competitive positioning

• Current standard of care in IBD and rheumatic diseases is limited by modest efficacy, frequent dosing, and safety concerns.

• Combination therapies have shown potential to break the therapeutic ceiling, as evidenced by the VEGA and DUET trials.

• Optimized components are expected to outperform existing combinations, with superior efficacy and safety profiles.

• Efficient trial designs and high funding levels ($750 million) position the company to deliver on its ambitious clinical agenda.

• Competitive advantage lies in having best-in-class, long-acting, high-concentration agents designed for co-formulation and single-injection delivery.